Is this your firm? Get featured or correct your listing →
Recent changes
- Jun 30, 2026Jun 30, 2026Invested in Flare Therapeutics (Series C, $85M) GlobeNewswire
Portfolio
1 totalRecent Investment Activity
1Track record: led 0 and participated in 1 of 1 tracked venture round · 1 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Flare Therapeutics | Series C | Participated | $85M | — | Pulse story |
Co-Investors
8Similar Firms
overlapping sector, stage or regionLatest Pulse
- Jul 7, 2026Cyllene Therapeutics Raises €33M for Gene TherapyCyllene Therapeutics, formerly EG 427, raised €33 million co-led by Merck Ventures to advance its HSV-1 gene-therapy platform toward treating neurogenic bladder conditions.→
- Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→
GordonMD Global Investments FAQ
What companies has GordonMD Global Investments invested in?
GordonMD Global Investments' portfolio includes Flare Therapeutics.
Who does GordonMD Global Investments co-invest with most?
In the rounds Value Add tracks, GordonMD Global Investments most often invests alongside Boxer Capital (1 shared deal), Casdin Capital (1 shared deal), Eli Lilly (1 shared deal), Eli Lilly and Company (1 shared deal), Invus (1 shared deal).
Sources & methodologyshow
Where these figures come from
- GlobeNewswireprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.